Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | FTO | Q9C0B1 | 7/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | ITPR3 | Q14573 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.36 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17970190 | 0.85 | KMT2A (0.66) | MEN1KMT2AMAPTHTTUSP2 | |
| SCHEMBL22434379 | 0.83 | MEN1 (0.62) | MEN1KMT2AMAPTHTTUSP2 | |
| SCHEMBL18677730 | 0.81 | MAPT (0.77) | MEN1KMT2AMAPTHTTUSP2 | |
| SCHEMBL29485015 | 0.80 | MEN1 (0.75) | MEN1KMT2AMAPTHTTUSP2 | |
| SCHEMBL29663660 | 0.80 | MEN1 (0.75) | MEN1KMT2AMAPTHTTUSP2 | |
| SCHEMBL6663204 | 0.80 | MEN1 (0.75) | MEN1KMT2AMAPTHTTUSP2 | |
| SCHEMBL13208827 | 0.79 | MEN1 (0.49) | MEN1KMT2AMAPTHTTUSP2 | |
| SCHEMBL16153115 | 0.78 | GSTP1 (0.55) | MEN1KMT2AMAPTHTTUSP2 | |
| SCHEMBL29672382 | 0.77 | MAPT (0.67) | MEN1KMT2AMAPTHTTUSP2 | |
| SCHEMBL31343967 | 0.77 | GSTP1 (0.58) | MEN1KMT2AMAPTHTTUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 447 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240401104-A1 | METHODS AND SYSTEMS FOR DETERMINING SUITABILITY OF COMPOSITIONS FOR INHIBITING GROWTH OF POLYMICROBIAL SAMPLES | CAP Diagnostics, LLC, dba Pathnostics | 2024-12-05 | — | — | US | claimed |
| US-20240247298-A1 | METHOD FOR DETECTING LIVE LACTIC ACID BACTERIA WITH CARBOHYDRATE METABOLISM ACTIVITY | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2024-07-25 | — | — | US | claimed |
| CN-117999356-A | Method for detecting live lactobacillus with sugar metabolism activity | 株式会社益力多本社 | 2024-05-07 | — | — | CN | claimed |
| EP-4350000-A1 | METHOD FOR DETECTING LIVE LACTIC ACID BACTERIA WITH CARBOHYDRATE METABOLISM ACTIVITY | Kabushiki Kaisha Yakult Honsha (JP) | 2024-04-10 | — | — | EP | claimed |
| CN-117625511-A | Automatic labeling and separating method, device and kit for extracellular vesicles | 上海思路迪生物医学科技有限公司 | 2024-03-01 | — | — | CN | claimed |
| US-20230218757-A1 | AUGMENTATION OF FIBROBLAST THERAPY USING EXTRACORPOREAL SHOCK WAVE THERAPY AND/OR TRANSFECTION OF BIOLOGICALLY RELEVANT MOLECULES | FIGENE, LLC | 2023-07-13 | — | — | US | claimed |
| US-20230193204-A1 | TREATMENT OF ERECTILE DYSFUNCTION BY FIBROBLAST ADMINISTRATION | FIGENE, LLC | 2023-06-22 | — | — | US | claimed |
| US-20230181647-A1 | TREATMENT OF OVARIAN FAILURE USING REGENERATIVE CELLS | FIGENE, LLC | 2023-06-15 | — | — | US | claimed |
| US-20230175035-A1 | METHOD FOR THE RAPID DETECTION OF BACTERIAL SPORES IN AN INDUSTRIAL PROCESS | ECOLAB USA INC. (US) | 2023-06-08 | — | — | US | claimed |
| US-20230096704-A1 | RNA-LOADED NANOPARTICLES AND USE THEREOF FOR THE TREATMENT OF CANCER | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2023-03-30 | — | — | US | claimed |
| US-11572547-B2 | Fusion proteins for the detection of apoptosis | UNIVERSITY OF CAPE TOWN (ZA) | 2023-02-07 | — | — | US | claimed |
| US-20230023269-A1 | INHIBITION OF TNF-ALPHA BY FIBROBLASTS AND FIBROBLAST EXOSOMES | FIGENE, LLC | 2023-01-26 | — | — | US | claimed |
| CN-115308186-B | fluorescence-pH biosensor and preparation method and application thereof | 广州市乾相生物科技有限公司 | 2023-01-17 | — | — | CN | claimed |
| WO-2022249910-A1 | METHOD FOR DETECTING LIVE LACTIC ACID BACTERIA WITH CARBOHYDRATE METABOLISM ACTIVITY | 株式会社ヤクルト本社 | 2022-12-01 | — | — | WO | claimed |
| CN-115308186-A | fluorescence-pH biosensor and preparation method and application thereof | 广州市乾相生物科技有限公司 | 2022-11-08 | — | — | CN | claimed |
| EP-4081228-A1 | INHIBITION OF TNF-ALPHA BY FIBROBLASTS AND FIBROBLAST EXOSOMES | Figene, LLC (US) | 2022-11-02 | — | — | EP | claimed |
| US-20220110979-A1 | FIBROBLAST REGENERATIVE CELLS | FIGENE, LLC | 2022-04-14 | — | — | US | claimed |
| EP-4741415-A2 | CHIMERIC MYD88 RECEPTORS FOR REDIRECTING IMMUNOSUPPRESSIVE SIGNALING AND RELATED COMPOSITIONS AND METHODS | Simurx, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| WO-2022029660-A1 | ANTI-IDIOTYPIC ANTIBODIES TO ROR1-TARGETED BINDING DOMAINS AND RELATED COMPOSITIONS AND METHODS | JUNO THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| CN-106659757-B | Superagonists, partial agonists and antagonists of interleukin 2 | 利兰斯坦福初级大学董事会 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230096704-A1 | RNA-LOADED NANOPARTICLES AND USE THEREOF FOR THE TREATMENT OF CANCER | SARNP, NSUN3, SNRPE | MEN1 3285/4885KMT2A 2172/4885MAPT 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.